GET DAILY SIGNALSNektar Therapeutics hits downward sloped trend line and gets bearish signal
Nektar Therapeutics (Nasdaq: NKTR) is a biopharmaceutical company that drugs for cancer, autoimmune diseases, and chronic pain. The company’s fundamental indicators are all over the place, but the stock has been trending lower since September.
If we connect the closing high from September with intraday high from February, it creates a trend line that the stock just hit in the last few days. We see the trend line on the daily chart, but what we don’t see on the daily chart is that the high from September was in close proximity to a gap in the chart from 2018. That gap was in the $70 area.
We also see that the daily stochastic readings and the 10-day RSI had reached overbought levels in the last few days before they turned lower on Friday and Monday.
The Tickeron AI Trend Prediction tool generated a bearish signal on the stock on May 10. The signal only showed a confidence level of 59%, but the past signals on Nektar have been successful 90% of the time. This prediction calls for a 2.5% decline in the next week.
I mentioned earlier that Nektar’s fundamentals are over the place. Earnings have been flat over the last three years and fell by 13% in the most recent quarterly report. Sales have increased by a rate of 128% per year over the last three years, but fell by 26% in the most recent quarter. The ROE is at 75.5% and the profit margin is at 57.2%. Both of those figures are well above average.
Contributor
Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.
NKTR in upward trend: price may jump up because it broke its lower Bollinger Band on October 01, 2026
NKTR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 35 of 38 cases where NKTR's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where NKTR's RSI Indicator exited the oversold zone, 28 of 38 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 74%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 49 of 62 cases where NKTR's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on NKTR as a result. In 66 of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
The Moving Average Convergence Divergence (MACD) for NKTR just turned positive on October 20, 2026. Looking at past instances where NKTR's MACD turned positive, the stock continued to rise in 33 of 43 cases over the following month. The odds of a continued upward trend are 77%.
Following a +3.19% 3-day Advance, the price is estimated to grow further. Considering data from situations where NKTR advanced for three days, in 195 of 244 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Bearish Trend Analysis
The 50-day moving average for NKTR moved below the 200-day moving average on October 13, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NKTR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for NKTR entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 38 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.397) is normal, around the industry mean (3.104). P/E Ratio (-6.038) is within average values for comparable stocks, (-0.958). Projected Growth (PEG Ratio) (1.100) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.907) among similar stocks. P/S Ratio (29.940) is also within normal values, averaging (439.647).
The Tickeron Price Growth Rating for this company is 89 (best 1 - 100 worst), indicating slightly worse than average price growth. NKTR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NKTR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of inhalation drug delivery systems
Industry Biotechnology
Advertisement